Skip to main content
Glama

Maptiler

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the read-only/idempotent annotations, the description discloses meaningful behavior: it cascades through multiple lookup endpoints, degrades gracefully when GLEIF or OpenFIGI is unavailable, returns unresolved identifiers explicitly under `unresolved`, and returns `figi_candidates` for ambiguous matches. It also explains source labeling and the ISIN-to-LEI mapping.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with use-case examples and the 'Use FIRST' directive. The company-type parenthetical is dense and long, but it earns its length by covering edge cases such as non-equity instruments, ambiguous matches, and source labeling that an agent would otherwise discover only after failed calls.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the burden of explaining returns; it covers identifiers per type, source provenance, unresolved fields, ambiguity behavior, and graceful degradation. It also provides input-form examples and the bond caveat, making the tool safe to call without external schema knowledge.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is already 100%, but the description adds the ISIN input form and explains how each enum type maps to outputs (CIK/ticker/LEI/FIGI vs RxCUI). It also reinforces the schema's warning to pass the issuer name only, not the full noun phrase, which directly prevents a common invocation error.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete natural-language triggers ('What's the ticker for…' / 'find the CIK for…') and then states the core job: resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. It enumerates two supported types (company, drug) and the identifiers each returns, making it clearly distinct from generic search tools.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly says 'Use FIRST whenever you have a name but need an ID,' giving a clear trigger condition. It also notes that using resolve_entity replaces 2-3 manual lookups and warns about passing full noun phrases for bonds. However, it does not name sibling tools or explicitly state when not to use this tool.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Maptiler toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.4/5.0
Disambiguation3/5

Many tools have distinct purposes, but there is overlap, e.g., ask_pipeworx vs ask_pipeworx_grounded vs deep_research all for data lookup, and multiple Polymarket tools. Descriptions are detailed enough to distinguish, but the set is confusing.

Naming Consistency2/5

Naming is highly inconsistent: snake_case (ai_visibility_check), verb_noun (resolve_entity), underscores (ask_pipeworx), and domain-specific prefixes (polymarket_). No consistent pattern across tools.

Tool Count2/5

With 38 tools spanning geospatial, data lookup, prediction markets, memory, feedback, etc., the count is too high for a coherent server. Many tools are one-off and unrelated to the server's name (Maptiler).

Completeness2/5

The tool set covers many areas but lacks obvious gaps for each domain (e.g., MapTiler only has 4 tools). The overall surface is a collection of unrelated features, not a cohesive domain, so completeness is poor for any single purpose.

Resources